|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_on1162016614 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
111222s2012 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020678437
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d OCLCF
|d VLY
|d OCLCO
|d N$T
|d YDXCP
|d E7B
|d EBLCP
|d AGLDB
|d VTS
|d AU@
|d STF
|d K6U
|d OCL
|d OCLCO
|d OCLCQ
|
| 015 |
|
|
|a GBB237775
|2 bnb
|
| 016 |
7 |
|
|a 016068635
|2 Uk
|
| 019 |
|
|
|a 833181544
|
| 020 |
|
|
|a 9781619426443
|q ebook
|
| 020 |
|
|
|a 1619426447
|
| 020 |
|
|
|z 1619426420
|q pbk.
|
| 020 |
|
|
|z 9781619426429
|q pbk.
|
| 029 |
1 |
|
|a AU@
|b 000051749801
|
| 029 |
1 |
|
|a DEBBG
|b BV041049678
|
| 029 |
1 |
|
|a DEBBG
|b BV043775331
|
| 029 |
1 |
|
|a DEBSZ
|b 472777866
|
| 035 |
|
|
|a (OCoLC)1162016614
|z (OCoLC)833181544
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RM373
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.37
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Rapamycin :
|b effectiveness, safety and drug interactions /
|c Martin J. Blanco and Agustina M. Torres, editors.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical/Nova Science Publishers, Inc.,
|c [2012]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Pharmacology - research, safety testing and regulation
|
| 490 |
1 |
|
|a Organ transplantation rsearch horizons
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 505 |
0 |
|
|a ""RAPAMYCIN""; ""EFFECTIVENESS, SAFETYAND DRUG INTERACTIONS""; ""PHARMACOLOGY -- RESEARCH, SAFETYTESTING AND REGULATION""; ""ORGAN TRANSPLANTATIONRESEARCH HORIZONS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""mTOR Inhibitors in Chronic LiverDiseases and Cancer""; ""Abstract""; ""1. Introduction""; ""2. mTOR Signaling in the Liver""; ""mTOR Inhibitors""; ""3. mTOR Inhibition in Chronic LiverDiseases""; ""Steatosis and Insulin Resistance""; ""Steatohepatitis and Fibrogenesis""; ""Cirrhosis""
|
| 505 |
8 |
|
|a ""4. Relevance of mTOR Inhibition inHepatocellular Carcinoma""""Conclusions""; ""References""; ""Starvation Profileof mTOR Inhibitors""; ""Abstract""; ""I. Introduction""; ""2. The Safety Profile of mTOR Inhibitors""; ""2.1. Hyperglycemia""; ""2.2. Dyslipidemia""; ""2.3. Asthenia""; ""2.4. Mucositis, Stomatitis and Mouth Sores""; ""2.5. Pulmonary Toxicity""; ""2.6. Skin Toxicity""; ""2.7. Infection and Malignancy""; ""2.8. Bone Marrow Suppression""; ""2.9. Renal Function Abnormalities""; ""3. mTOR Function in Normal CellPhysiology""; ""3.1. Regulation of Growth Factor Signaling""
|
| 505 |
8 |
|
|a ""3.2. Regulation of Cell Growth and Metabolism""""4. mTOR Integrates Energy-SensingPathways""; ""4.1. AKT: The Link betweenMetabolism and Extracellular Signals""; ""4.2. mTOR Controls the Interfacebetween Nutrient Sensing and Metabolism""; ""4.3. AMPK: A Low-Energy Checkpoint""; ""4.4. AMP-Activated Kinase Controls the Metabolic Checkpoint""; ""5. mTOR Toxicity on Signaling Pathways""; ""6. Leptin""; ""7. Body Weight and Feeding""; ""8. Cross-Talk among mTOR/PKA/AMP""; ""Conclusion""; ""References""
|
| 505 |
8 |
|
|a ""Identification of CandidateBiomarkers Predicting Responseto Rapalogs Therapyin Human Cancer""""Abstract""; ""Introduction""; ""Pathway-based Identificationof Predictive Biomarker""; ""Omics-based Identificationof Predictive Biomarker""; ""Conclusion""; ""References""; ""Influence of Everolimus DrugRegime on Blood Cell Subsetsin Kidney Transplant Patients""; ""Abstract""; ""Introduction""; ""Materials and Methods""; ""Blood Leukocyte and LymphocyteSubset Measurement""; ""Results""; ""Discussion""; ""References""
|
| 505 |
8 |
|
|a ""The Emerging Mechanismof Limited Therapeutic Efficacyof Rapamycin for Cancers""""Abstract""; ""Introduction""; ""a) Overview of Rapamycin""; ""b) Overview of the mTOR Signaling Pathway""; ""c) Overview of Limited Clinical Application of Rapamycinand Its Analogs for Cancer""; ""Rapamycin Can Only Partially InhibitmTORC1 Activity""; ""Rapamycin Cannot Inhibit mTORC2Activity upon Acute Treatment""; ""PI3K/Akt Feedback Loop NegativelyRegulates mTORC1 Activity""; ""Conclusions""; ""References""; ""Rapamycin Controls MultipleSignalling Pathways Involvedin Cancer Cell Survival*""; ""Abstract""
|
| 546 |
|
|
|a English.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Rapamycin.
|
| 650 |
|
2 |
|a Sirolimus
|
| 650 |
|
6 |
|a Sirolimus.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Rapamycin.
|2 fast
|0 (OCoLC)fst01089963
|
| 700 |
1 |
|
|a Blanco, Martin J.,
|e editor.
|
| 700 |
1 |
|
|a Torres, Agustina M.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Rapamycin
|d New York : Nova Science Publishers, c2012.
|z 9781619426429 (pbk.)
|w (DLC) 2011946012
|
| 830 |
|
0 |
|a Pharmacology-research, safety testing, and regulation series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541043
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3017759
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10654730
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 541043
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 7422664
|
| 994 |
|
|
|a 92
|b IZTAP
|
